National Comprehensive Cancer Network (2023) NCCN clinical practice guidelines in oncology (NCCN Guidelines®) Non-small cell lung cancer, Version 3.2023 [Internet]. National Comprehensive Cancer Network. p. Version 3. Available from: https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf

Gierman HJ, Pai N, Catasus C, Tam A, Labrador M, Donaldson J, et al. A retrospective three-year analysis using real-world data on uptake of broad-based NextGen sequencing panels in community oncology practices. J Clin Oncol. 2020;38(15_suppl):e13668–e13668. https://doi.org/10.1200/JCO.2020.38.15_suppl.e13668.

Article  Google Scholar 

Paz-Ares L, Gondos A, Saldana D, Thomas M, Mascaux C, Bubendorf L, et al. Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: a contemporary clinical practice patterns study. Lung Cancer. 2022;167(October 2021):41–8. https://doi.org/10.1016/j.lungcan.2022.01.021.

Article  CAS  Google Scholar 

de Moor JS, Gray SW, Mitchell SA, Klabunde CN, Freedman AN. Oncologist confidence in genomic testing and implications for using multimarker tumor panel tests in practice. JCO Precis Oncol. 2020;4:620–31.

Article  Google Scholar 

Mileham KF, Schenkel C, Bruinooge SS, Freeman-Daily J, Basu Roy U, Moore A, et al. Defining comprehensive biomarker-related testing and treatment practices for advanced non-small-cell lung cancer: results of a survey of U.S. oncologists. Cancer Med. 2022;11(2):530–8.

Article  Google Scholar 

West HJ, Lovly CM. Ferrying oncologists across the chasm of interpreting biomarker testing reports: systematic support needed to improve care and decrease disparities. JCO Oncol Pract. 2023. https://doi.org/10.1200/OP.23.00010.

Article  Google Scholar 

Hsiao SJ, Sireci AN, Pendrick D, Freeman C, Fernandes H, Schwartz GK, et al. Clinical utilization, utility, and reimbursement for expanded genomic panel testing in adult oncology. JCO Precis Oncol. 2020;4:1038–48.

Article  Google Scholar 

Hall MJ, D’Avanzo P, Chertock Y, Brajuha J, Bass SB. Oncologists’ perceptions of tumor genomic profiling and the communication of test results and risks. Public Health Genomics. 2021;24(5–6):304–9.

Article  Google Scholar 

Drilon A, Wang L, Arcila ME, Balasubramanian S, Greenbowe JR, Ross JS, et al. Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in lung adenocarcinomas otherwise negative for such alterations by other genomic testing approaches. Clin Cancer Res. 2015;21(16):3631–9. https://doi.org/10.1158/1078-0432.CCR-14-2683.

Article  PubMed Central  Google Scholar 

Ali SM, Hensing T, Schrock AB, Allen J, Sanford E, Gowen K, et al. Comprehensive genomic profiling identifies a subset of crizotinib-responsive ALK -rearranged non-small cell lung cancer not detected by fluorescence in situ hybridization. Oncologist. 2016;21(6):762–70.

Article  PubMed Central  Google Scholar 

Waterhouse DM, Tseng WY, Espirito JL, Robert NJ. Understanding contemporary molecular biomarker testing rates and trends for metastatic NSCLC among community oncologists. Clin Lung Cancer. 2021;22(6):e901–10. https://doi.org/10.1016/j.cllc.2021.05.006.

Article  Google Scholar 

Evangelist MC, Butrynski JE, Paschold JC, Ward PJ, Spira AI, Ali K, et al. Contemporary biomarker testing rates in both early and advanced NSCLC: Results from the MYLUNG pragmatic study. J Clin Oncol. 2023;41(16_suppl):9109–9109.

Article  Google Scholar 

Wu N, Ge W, Quek RGW, Gleeson M, Pouliot JF, Dietz H, et al. Trends in real-world biomarker testing and overall survival in US patients with advanced non-small-cell lung cancer. Futur Oncol. 2022;18(39):4385–97.

Article  CAS  Google Scholar 

Tomlins SA, Hovelson DH, Suga JM, Anderson DM, Koh HA, Dees EC, et al. Real-world performance of a comprehensive genomic profiling test optimized for small tumor samples. JCO Precis Oncol. 2021;5:1312–24.

Article  Google Scholar 

Diep R, Macdonald M, Cooper R, Grzegorczyk A, Rakocevic R, Chang C-F, et al. Biopsy method and needle size on success of next-generation sequencing in NSCLC: a brief report. JTO Clin Res Reports. 2023;4(4): 100497.

Article  Google Scholar 

Sadik H, Pritchard D, Keeling D-M, Policht F, Riccelli P, Stone G, et al. Impact of clinical practice gaps on the implementation of personalized medicine in advanced non–small-cell lung cancer. JCO Precis Oncol. 2022. https://doi.org/10.1200/PO.22.00246.

Article  PubMed Central  Google Scholar 

Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, et al. Non-small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2022;20(5):497–530.

Article  Google Scholar 

Conroy JM, Pabla S, Glenn ST, Seager RJ, Van Roey E, Gao S, et al. A scalable high-throughput targeted next-generation sequencing assay for comprehensive genomic profiling of solid tumors. PLoS ONE. 2021;16(12): e0260089. https://doi.org/10.1371/journal.pone.0260089.

Article  CAS  PubMed Central  Google Scholar 

von Ahlfen S, Missel A, Bendrat K, Schlumpberger M. Determinants of RNA quality from FFPE samples. PLoS ONE. 2007;2(12):1–7.

Google Scholar 

Hedegaard J, Thorsen K, Lund MK, Hein A-MK, Hamilton-Dutoit SJ, Vang S, et al. Next-generation sequencing of RNA and DNA isolated from paired fresh-frozen and formalin-fixed paraffin-embedded samples of human cancer and normal tissue. PLoS ONE. 2014;9(5): e98187.

Article  ADS  PubMed Central  Google Scholar 

Locy H, Correa RJM, Autaers D, Schiettecatte A, Jonckheere J, Waelput W, et al. Overcoming the challenges of high quality RNA extraction from core needle biopsy. Biomolecules. 2021;11(5):1–19.

Article  Google Scholar 

Bruno R, Fontanini G. Next generation sequencing for gene fusion analysis in lung cancer: a literature review. Diagnostics. 2020;10(8):521.

Article  CAS  PubMed Central  Google Scholar 

Gierman HJ, Goldfarb S, Labrador M, Weipert CM, Getty B, Skrzypczak SM, et al. Genomic testing and treatment landscape in patients with advanced non-small cell lung cancer (aNSCLC) using real-world data from community oncology practices. J Clin Oncol. 2019;37(15_Suppl):1585–1585. https://doi.org/10.1200/JCO.2019.37.15_suppl.1585.

Article  Google Scholar 

Roberts TJ, Kehl KL, Brooks GA, Sholl L, Wright AA, Landrum MB, et al. Practice-level variation in molecular testing and use of targeted therapy for patients with non-small cell lung cancer and colorectal cancer. JAMA Netw Open. 2023;6(4):E2310809.

Article  PubMed Central  Google Scholar 

Calles A, Riess JW, Brahmer JR. Checkpoint Blockade in lung cancer with driver mutation: choose the road wisely. Am Soc Clin Oncol Educ B. 2020;40:372–84.

Article  Google Scholar 

Zhou C, Solomon B, Loong HH, Park K, Pérol M, Arriola E, et al. First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion-positive NSCLC. N Engl J Med. 2023;21:1–12. https://doi.org/10.1056/NEJMoa2309457.

Article  Google Scholar 

Nesline MK, Knight T, Colman S, Patel K. economic burden of checkpoint inhibitor immunotherapy for the treatment of non-small cell lung cancer in US clinical practice. Clin Ther. 2020;42(9):1682-1698.e7. https://doi.org/10.1016/j.clinthera.2020.06.018.

Article  CAS  Google Scholar 

Nesline M, Pabla S, Lee YH, DePietro P, Zhang S, Klein RD, et al (2022) Comprehensive genomic and immune profiling (CGIP) treatment patterns and survival in non-small cell lung cancer (NSCLC). Am Soc Clin Oncol

Bhandari NR, Hess LM, He D, Peterson P. Biomarker testing, treatment, and outcomes in patients with advanced/metastatic non-small cell lung cancer using a real-world database. J Natl Compr Canc Netw. 2023;21(9):934–44.

Article  Google Scholar 

Stricker T, Jain N, Yu E, Ma E, Schuldt R, Wang R, et al. Clinical value of timely targeted therapy (TT) for patients with advanced non-small cell lung cancer (aNSCLC) with actionable driver oncogenes (ADO). J Clin Oncol. 2023;41(16_Suppl):6507–6507.

Article  Google Scholar 

Aggarwal C, Marmarelis ME, Hwang W-T, Scholes DG, McWilliams TL, Singh AP, et al. Association between availability of molecular genotyping results and overall survival in patients with advanced nonsquamous non–small-cell lung cancer. JCO Precis Oncol. 2023. https://doi.org/10.1200/PO.23.00191.

Article  Google Scholar 

Scott JA, Lennerz J, Johnson ML, Gordan LN, Dumanois RH, Quagliata L, et al. Compromised outcomes in stage IV non – small-cell lung cancer with actionable mutations initially treated without tyrosine kinase inhibitors: a retrospective analysis of real-world data. JCO Oncol Pract. 2023. https://doi.org/10.1200/OP.22.00611.

Article  PubMed Central  Google Scholar 

Levy BP, Nguyen D, Shih Y-H, Gorritz M, Cai B, Caro N, et al. Association between real-world, upfront, next-generation sequencing and overall survival (OS) in advanced non–small-cell lung cancer (aNSCLC) in the United States. J Clin Oncol. 2023;41(16_Suppl):9117–9117.

Article  Google Scholar 

Pennell NA, Mutebi A, Zhou Z-Y, Ricculli ML, Tang W, Wang H, et al. Economic impact of next-generation sequencing versus single-gene testing to detect genomic alterations in metastatic non–small-cell lung cancer using a decision analytic model. JCO Precis Oncol. 2019;3:1–9. https://doi.org/10.1200/PO.18.00356.

Article  Google Scholar 

Vanderpoel J, Stevens AL, Emond B, Lafeuille MH, Hilts A, Lefebvre P, et al. Total cost of testing for genomic alterations associated with next-generation sequencing versus polymerase chain reaction testing strategies among patients with metastatic non-small cell lung cancer. J Med Econ. 2022;25(1):457–68. https://doi.org/10.1080/13696998.2022.2053403.

Article  Google Scholar 

Wong W, Sheinson D, Liu Y, To TM. Costs associated with the use of multigene panel tests in three solid tumor types and the impact on insurance premiums. Futur Oncol. 2023;19(10):705–14. https://doi.org/10.2217/fon-2023-0094.

Article  CAS  Google Scholar 

Harvey MJ, Cunningham R, Sawchyn B, Montesion M, Reddy P, McBride A, et al. Budget impact analysis of comprehensive genomic profiling in patients with advanced non–small-cell lung cancer. JCO Precis Oncol. 2021;5:1611–24. https://doi.org/10.1200/PO.20.00540.

Article  Google Scholar 

Stenzinger A, Cuffel B, Paracha N, Vail E, Garcia-Foncillas J, Goodman C, et al. Supporting biomarker-driven therapies in oncology: a genomic testing cost calculator. Oncologist. 2023;28(5):E242–53.

Article  PubMed Central  Google Scholar 

Waterhouse DM, Ward P, Arnal S, Neubauer M, Drosick DR, Davies D, et al. Closing the testing gap: standardization of comprehensive biomarker testing for metastatic non–small-cell lung cancer in a large community oncology practice. JCO Oncol pract. 2023. https://doi.org/10.1200/OP.22.00817?role=tab.

Article  Google Scholar 

Kästner A, Kron A, van den Berg N, Moon K, Scheffler M, Schillinger G, et al. Evaluation of the effectiveness of a nationwide precision medicine program for patients with advanced non-small cell lung cancer in Germany: a historical cohort analysis. Lancet Reg Heal - Eur. 2024;36:100788.

Article  Google Scholar 

Sholl LM, Aisner DL, Varella-Garcia M, Berry LD, Dias-Santagata D, Wistuba II, et al. Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the lung cancer mutation consortium experience. J Thorac Oncol. 2015;10(5):768–77.

Article  CAS  PubMed Central  Google Scholar 

Aggarwal C, Thompson JC, Black TA, Katz SI, Fan R, Yee SS, et al. Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer. JAMA Oncol. 2019;5(2):173–80.

Article